Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region

Journal of International Medical Research

Volumn 39, Issue 2, 2011, Pages 366-377

  Jambart, S ^a   Ammache, Z ^b   Haddad, F ^c   Younes, A ^d   Hassoun, A ^e   Abdalla, K ^f   Abou Selwan, C ^g   Sunna, N ^g   Wajsbrot, D ^g   Youseif, E ^g  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b CLEMENCEAU MEDICAL CENTER   (Lebanon)

^c KING HUSSEIN MEDICAL CENTER   (Jordan)

^d Private Practice   (Jordan)

^e Dubai   (United Arab Emirates)

^f ALEXANDRIA UNIVERSITY   (Egypt)

^g PFIZER INC   (United States)

Author keywords

Arabic region; Diabetes; Epidemiology; Neuropathic pain; Painful DPN; Peripheral neuropathy; Prevalence

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; DOULEUR NEUROPATHIQUE 4 QUESTIONNAIRE; EGYPT; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JORDAN; KUWAIT; LEBANON; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PREDICTION; PREVALENCE; SCHOOL CHILD; SEX RATIO; UNITED ARAB EMIRATES;

EID: 79955657951     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900204     Document Type: Article

References (39)

1. Motlagh B, O'Donnell M, Yusuf S: Prevalence of cardiovascular risk factors in the Middle East: a systematic review. Eur J Cardiovasc Prev Rehabil 2009; 16: 268-280.
2. Harris M, Eastman R, Cowie C: Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care 1993; 16: 1446-1452.
3. Boulton AJ, Malik RA, Arezzo JC: Diabetic somatic neuropathies. Diabetes Care 2004; 27: 1458-1486.
4. Sulimani RA, Famuyiwa OO, Mekki MO, et al: Pattern of diabetic foot lesions in Saudi Arabia: Experience from King Khalid University Hospital, Riyadh. Ann Saudi Med 1991; 11: 47-50.
5. Nielsen JV: Peripheral neuropathy, hypertension, foot ulcers and amputations among Saudi Arabian patients with type 2 diabetes. Diabetes Res Clin Pract 1998; 41: 63-69.
6. Akbar DH, Mira SA, Zawawi TH, et al: Subclinical diabetic neuropathy: a common complication in Saudi diabetics. Saudi Med J 2000; 21: 433-437.
7. Al Mahroos F, Al Roomi K: Diabetic neuropathy, foot ulceration, peripheral vascular disease and potential risk factors among patients with diabetes in Bahrain: a nationwide primary care diabetes clinic-based study. Ann Saudi Med 2007; 27: 25-31.
8. Al Maskari F, El Sadig M: Prevalence of risk factors for diabetic foot complications. BMC Fam Pract 2007; 8: 59.
9. Saadi H, Carruthers SG, Nagelkerke N, et al: Prevalence of diabetes mellitus and its complications in a population-based sample in Al Ain, United Arab Emirates. Diabetes Res Clin Pract 2007; 78: 369-377.
10. Halawa MR, Karawagh A, Zeidan A, et al: Prevalence of painful diabetic peripheral neuropathy among patients suffering from diabetes mellitus in Saudi Arabia. Curr Med Res Opin 2010; 26: 337-343.
11. Vinik AI, Mehrabyan A: Diabetic neuropathies. Med Clin North Am 2004; 88: 947-999.
12. Davies M, Brophy S, Williams R, et al: The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29: 1518-1522.
13. Sadosky A, McDermott AM, Brandenburg NA, et al: A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract 2008; 8: 45-56.
14. Treede R-D, Jensen TS, Campbell JN, et al: Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008; 70: 1630-1635.
15. Meyer-Rosberg K, Kvarnström A, et al: Peripheral neuropathic pain: a multidimensional burden for patients. Eur J Pain 2001; 5: 379-389.
16. McDermott AM, Toelle TR, Rowbotham DJ, et al: The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006; 10: 127-135.
17. Jensen MP, Chodroff MJ, Dworkin RH: The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007; 68: 1178-1182.
18. O'Connor AB: Neuropathic pain: quality-of-life impact, costs, and cost effectiveness of therapy. Pharmacoeconomics 2009; 27: 95-112.
19. Dworkin RH, Malone DC, Panarites CJ, et al: Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain 2010; 11: 360-368.
20. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
21. Franklin GM, Kahn LB, Baxter J, et al: Sensory neuropathy in noninsulin dependent diabetes mellitus. The San Luis Valley Diabetes Study. Am J Epidemiol 1990; 131: 633-643.
22. Smith AG, Singleton JR: Impaired glucose tolerance and neuropathy. Neurologist 2008; 14: 23-29.
23. Tesfaye S, Chaturvedi N, Eaton SE, et al: Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341-350.
24. Toth C, Rong LL, Yang C, et al: Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 2008; 57: 1002-1017.
25. Obrosova IG: Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics 2009; 6: 638-647.
26. King GL, Das Evcimen N: Role of protein kinase C in diabetic complications. Expert Rev Endocrinol Metab 2010; 5: 77-88.
27. US Food and Drug Administration (FDA): Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. Rockville: US Food and Drug Administration, March 2005 (available at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126834.pdf).
28. Bouhassira D, Attal N, Fermanian J, et al: Development and validation of the neuropathic pain symptom inventory. Pain 2004; 108: 248-257.
29. Bouhassira D, Attal N, Alchaar H, et al: Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005; 114: 29-36.
30. Harifi G, Ouilki I, El Bouchti I, et al: Validity and reliability of the Arabic adapted version of the DN4 questionnaire (Douleur Neuropathique 4 questions) for differential diagnosis of pain syndromes with a neuropathic or somatic component. Pain Pract 2011; 11: 139-147.
31. Veves A, Backonja M, Malik RA: Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med 2008; 9: 660-674.
32. Uddin I, Ahmad TJ, Kurkuman AR, et al: Diabetes education: its effects on glycemic control. Ann Saudi Med 2001; 21: 120-122.
33. Habib SS, Aslam M: Risk factors, knowledge and health status in diabetic patients. Saudi Med J 2003; 24: 1219-1224.
34. Youssef AA, El Mahalli AA, Akl OA et al: Quality of diabetes care in primary care setting in Egypt: an example of health sector reform in developing countries. J Egypt Public Health Assoc 2006; 81: 301-320.
35. Al-Elq AH: Current practice in the management of patients with type 2 diabetes mellitus in Saudi Arabia. Saudi Med J 2009; 30: 1551-1556.
36. Freynhagen R, Bennett MI: Diagnosis and management of neuropathic pain. BMJ 2009; 339: 391-395.
37. O'Connor AB, Dworkin RH: Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009; 122(10 suppl): S22-S32.
38. Moulin DE, Clark AJ, Gilron I, et al: Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007; 12: 13-21.
39. Bohlega S, Alsaadi T, Amir A, et al: Guidelines for the pharmacological treatment of peripheral neuropathic pain: expert panel recommendations for the Middle East region. J Int Med Res 2010; 38: 295-317.